Background: Exploratory analysis from CHAMPION-AF trials showed that cangrelor has significantly lower bleeding rates with comparable ischemic events when compared to bailout glycoprotein IIb/IIIa inhibitors (GPI) in patients undergoing percutaneous coronary intervention (PCI). However, to date, there are no real-world studies comparing both adjunctive antiplatelet therapies. Thus, we performed this study to evaluate the safety and effectiveness of cangrelor during PCI.